Plain-English translation of NCT05650619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
RESOLVE is a long-term study that tracks patients with two specific kidney diseases—focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)—before and after they receive a kidney transplant. The study collects medical records, blood samples, and patient experiences to understand how often these diseases return after transplant and what happens to patients over many years. This information will help doctors better predict and prevent disease recurrence in future transplant patients.
When patients with FSGS or MCD receive a kidney transplant, their disease sometimes comes back in the new kidney. Researchers don't fully understand why this happens, how often it happens, or what can be done to prevent it. This study aims to answer those questions so doctors can better care for transplant patients with these conditions.
You likely qualify if…
You likely don't qualify if…
Depending on when you join, you may be enrolled before your transplant or afterward. Participants share their existing medical records and may provide new blood or urine samples and answer surveys about their health and quality of life. The study follows patients across their lifetime, so you would remain in contact with researchers over many years as they monitor your kidney health and collect information about how you're doing.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States